Aberrant glycosylation of the anti-Thomsen-Friedenreich glycotope immunoglobulin G in gastric cancer patients

doi:10.3748/wjg.v19.i23.3573

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 19, Issue 23

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (4506)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-5) series, Tables (1-2) series.

Item

Count

PDF

343

HTML

3681

Figures (1-5)

263

Tables (1-2)

219

Sum=4506

Jun 21, 2013 (publication date) through Nov 27, 2024

Times Cited of This Article

Times Cited (13)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Original Article

World J Gastroenterol. Jun 21, 2013; 19(23): 3573-3582
Published online Jun 21, 2013. doi: 10.3748/wjg.v19.i23.3573

Full Size Figure Download Figure

Figure 1 Thomsen-Friedenreich glycotope-IgG level in patients with stomach cancer and controls. A: Box plots of anti-TF IgG levels (medians, ranges and quartiles) in controls and cancer patients; B: Anti-TF IgG levels in cancer patients by stage. Significantly higher in stage 1 compared with stages 2, 3 and 4 (P = 0.02, 0.001 and 0.01, respectively). P values were calculated by the Mann-Whitney U test.

Citation: Kodar K, Izotova J, Klaamas K, Sergeyev B, Järvekülg L, Kurtenkov O. Aberrant glycosylation of the anti-Thomsen-Friedenreich glycotope immunoglobulin G in gastric cancer patients. World J Gastroenterol 2013; 19(23): 3573-3582
URL: https://www.wjgnet.com/1007-9327/full/v19/i23/3573.htm
DOI: https://dx.doi.org/10.3748/wjg.v19.i23.3573